- All eight treated brain cancer patients in the trial remain alive as of November 11, 2026; median overall survival has not been reached, with a median follow-up of 6.9 months from trial enrollment (range 3.1 to 11.6 months) in the six patients who have reached response assessment - - All six patients who have reached response assessment achieved a RANO objective response as their best overall response, with five patients showing complete responses (83.3%), including a previously reported stabl
Detailed price information for Alpha Tau Medical Ltd Cl A (DRTS-Q) from The Globe and Mail including charting and trades.
Detailed price information for Alpha Tau Medical Ltd Cl A (DRTS-Q) from The Globe and Mail including charting and trades.
WSW, NY, October 19th, 2026, FinanceWireFDA clearance doubles REGAIN’s permitted enrollment and broadens its clinical assessments, as Alpha Tau prepares to present updated results in November.Alpha Tau Medical
JERUSALEM, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that company management will participate in the following investor conferences in October 2026. Event:Fall Focus: Barclays Biotech 1x1 DayFormat:1x1 MeetingsDate:Tuesday, October 6, 2026Location:New York, NY Event:Investment Generation ConferenceFormat:PresentationDate:Thursday, Octob
JERUSALEM, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will participate in the following investor conferences in September 2026. Event:Citi's 2026 Biopharma Back to School ConferenceFormat:1x1 MeetingsDate:Wednesday, September 9, 2026Location:New York, NY Event:H.C. Wainwright 28th Annual Global Investor ConferenceFor
- IMPACT, a multicenter pilot study of Alpha DaRT® for newly diagnosed unresectable pancreatic cancer, expanded enrollment three times over the course of the study, from an original enrollment of 12 patients to a total of 48 treated patients, driven by overwhelming demand from patients and clinicians - - Alpha DaRT is delivered as a one-time add-on alongside standard first-line chemotherapy, an approach supported by the favorable safety profile observed in the earlier Israeli and Canadian studie
This is the newest page. Registered accounts read further back.